Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10

Summary

Unanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarintreated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding.

Keywords

Thrombosis - oral anticoagulants - acquired - coagulation disorders - Haemostasis

• References

• 1 Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record link-age study. Br Med J 2002; 325: 1073-1075.
• 2 Ansell J, Hirsh J, Poller L. et al The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) (Suppl) 204S-233S.
• 3 Palareti G, Leali N, Coccheri S. et al Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
• 4 Palareti G, Cosmi B. Bleeding with anticoagulation therapy – who is at risk, and how best to identify such patients. Thromb Haemost 2009; 102: 268-278.
• 5 Baker P, Gleghorn A, Tripp T. et al Reversal of asymptomatic over-anticoagulation by orally administered vitamin K. Br J Hematol 2006; 133: 331-336.
• 6 Dezee KJ, Shimeall WT, Douglas KM. et al Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 2006; 166: 391-397.
• 7 Gunther KE, Conway G, Leibach L. et al Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10. Thromb Res 2004; 113: 205-209.
• 8 Lubetsky A, Shasha Y, Olchovsky D. et al Impact of pretreatment INR level on the effect of intravenous low dose vitamin K in patients with excessive anticoagulation. Thromb Haemost 2003; 90: 71-76.
• 9 Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 04: 1853-1863.
• 10 Denas G, Cucchini U, Iliceto S. et al An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International Normalised Ratio above 10.0. Thromb Haemost 2009; 101: 410-411.
• 11 Crowther M, Ageno W, Garcia D. et al Vitamin K versus placebo in the correction of overanticoagulated patients receiving warfarin. A randomized trial. Ann Intern Med 2009; 150: 293-300.
• 12 Beinema M, Brouwers JR, Schalekamp T. et al Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008; 100: 1052-1057.
• 13 Ageno W, Crowther M, Steidl L. et al Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial. Thromb Haemost 2002; 88: 48-51.
• 14 Penning-van Beest FJ, Rosendaal FR, Grobbee DE. et al Course of the international Normalized Ratio in response to oral vitamin K1 in patients overanti-coagulated with phenprocoumon. Br J Haematol 1999; 104: 241-245.